<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Aminoglycosides</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Aminoglycosides</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Aminoglycosides</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Drew, PharmD, MS, FCCP, FIDP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David C Hooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 12, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The aminoglycoside class of antibiotics consists of many different agents. In the United States, <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>, <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a>, <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a>, <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">plazomicin</a>, <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a>, <a class="drug drug_general" data-topicid="9686" href="/z/d/drug information/9686.html" rel="external">neomycin</a>, and <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> are approved by the US Food and Drug Administration (FDA) and are available for clinical use. Of these, gentamicin, tobramycin, and amikacin are the most frequently prescribed by intramuscular or intravenous injection for systemic treatment. </p><p>The most common clinical application (either alone or as part of combination therapy) of the aminoglycosides is for the treatment of serious infections caused by aerobic gram-negative bacilli [<a href="#rid1">1,2</a>]. While less common, aminoglycosides (in combination with other agents) have also been used for the treatment of select gram-positive infections. In addition, certain aminoglycosides have demonstrated clinically relevant activity against protozoa (<a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a>), <em>Neisseria gonorrhoeae</em> (spectinomycin, not available in the United States), and mycobacterial infections (<a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a>, <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a>, and [most commonly] <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a>).</p><p>This topic will review basic issues related to the clinical use of parenteral aminoglycosides, including mechanism of action, spectrum of activity, and adverse effects. Dosing and monitoring of aminoglycosides and administration in certain patient populations are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/475.html" rel="external">"Dosing and administration of parenteral aminoglycosides"</a>.)</p><p>The multiple clinical settings in which the aminoglycosides may be used are also discussed separately in the appropriate topic reviews. (See  <a class="medical medical_review" href="/z/d/html/3149.html" rel="external">"Gram-negative bacillary bacteremia in adults", section on 'Indications and rationale for combination therapy'</a> and  <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Intravenous antibiotics'</a> and  <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">"Antimicrobial therapy of left-sided native valve endocarditis", section on 'Viridans streptococci and S. bovis/S. equinus complex'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span>The aminoglycosides primarily act by binding to the aminoacyl site of 16S ribosomal RNA within the 30S ribosomal subunit, leading to misreading of the genetic code and inhibition of translocation [<a href="#rid3">3,4</a>]. The initial steps required for peptide synthesis, such as binding of mRNA and the association of the 50S ribosomal subunit, are uninterrupted, but elongation fails to occur due to disruption of the mechanisms for ensuring translational accuracy [<a href="#rid4">4</a>]. The ensuing antimicrobial activity is usually bactericidal against susceptible aerobic gram-negative bacilli.</p><p>Aminoglycosides initially penetrate the organism by disrupting the magnesium and calcium bridges between lipopolysaccharide moieties. They are transported across the cytoplasmic membrane in an energy-dependent manner. This step can be inhibited in vitro by divalent cations, increased osmolality, acidic pH, and an anaerobic environment [<a href="#rid4">4</a>].</p><p>The microbiologic activity of aminoglycosides is pH dependent. As a result, the antimicrobial effect may be reduced at the low pH found in lung and bronchial secretions. In an in vitro study, for example, the minimum inhibitory concentration (MIC) of aminoglycosides against five strains of <em>Escherichia</em> <em>coli</em> was increased almost five-fold at a pH &lt;6.5 [<a href="#rid5">5</a>]. Activity may also be reduced in the presence of biofilms, such as those seen with mucoid-producing strains of <em>Pseudomonas aeruginosa</em> commonly isolated in cystic fibrosis patients. Studies have demonstrated reduced aminoglycoside (in particular <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a>) activity in conditions simulating epithelial lining fluid [<a href="#rid6">6,7</a>]. </p><p class="headingAnchor" id="H6"><span class="h1">SPECTRUM OF ACTIVITY</span><span class="headingEndMark"> — </span>In general, aminoglycosides are active across a broad spectrum of aerobic gram-negative and gram-positive organisms, including mycobacteria. Of note, anaerobic bacteria are intrinsically resistant to aminoglycosides. </p><p class="headingAnchor" id="H120095666"><span class="h2">Gram-negative organisms</span><span class="headingEndMark"> — </span>Aminoglycosides exhibit potent in vitro activity against a wide range of aerobic gram-negative pathogens, including Enterobacteriaceae, <em>Pseudomonas</em> spp, <em>Acinetobacter </em>spp, and <em>Haemophilus influenzae</em>. However, in vitro activity against <em>Burkholderia cepacia</em>, <em>Stenotrophomonas maltophilia</em>, and anaerobic bacteria is usually poor or absent.</p><p>Differences may exist among the in vitro potencies of the various aminoglycosides. As an example, <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> usually demonstrates superior in vitro activity (one- to twofold dilutions) to <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> against <em>Serratia</em> spp, while tobramycin is usually more potent than gentamicin against <em>P. aeruginosa</em> [<a href="#rid8">8</a>]. Among the Enterobacteriaceae, <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">plazomicin</a> has the most potent activity in vitro, followed by <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a> and then gentamicin [<a href="#rid9">9,10</a>]. The magnitude of these differences can vary between different strains across different institutions. Plazomicin also retains activity against many Enterobacteriaceae resistant to other aminoglycosides. (See <a class="local">'Gram-negative organisms'</a> below.) </p><p class="headingAnchor" id="H120095672"><span class="h2">Gram-positive organisms</span><span class="headingEndMark"> — </span>Aminoglycosides also demonstrate activity in vitro against gram-positive organisms, such as <em>Staphylococcus aureus</em>. However, most authorities believe these drugs are not adequate therapy as monotherapy for serious infections caused by <em>S. aureus</em>. Aminoglycoside activity against pneumococci is generally considered insufficient for clinical application against these organisms. Aminoglycosides are not active alone against streptococci and enterococci, although may have additive or synergistic effects against these pathogens when combined with other agents and in the absence of high-level resistance. (See <a class="local">'Combination antibacterial therapy'</a> below.)</p><p class="headingAnchor" id="H120095678"><span class="h2">Mycobacteria</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">Streptomycin</a>, <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a>, and <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a> demonstrate favorable activity in vitro against mycobacteria [<a href="#rid11">11,12</a>]. Specifically, streptomycin is particularly active against <em>Mycobacterium tuberculosis</em>, and amikacin is generally the most active aminoglycoside in vitro against <em>Mycobacterium fortuitum</em>, <em>Mycobacterium abscessus</em>, and <em>Mycobacterium chelonae</em>. </p><p class="headingAnchor" id="H120096104"><span class="h1">RESISTANCE</span><span class="headingEndMark"> — </span>Compared with other classes of antibiotics, the aminoglycosides have demonstrated relative stability against the development of resistance during treatment. Both intrinsic and acquired mechanisms of resistance to aminoglycosides have been described. </p><p>While cross resistance between the specific aminoglycoside agents does occur, it may be incomplete. Therefore, individual agents should be tested for in vitro susceptibility against the isolated pathogen whenever possible.</p><p class="headingAnchor" id="H120096130"><span class="h2">Gram-negative organisms</span><span class="headingEndMark"> — </span>Resistance of gram-negative organisms to aminoglycosides occurs by two major mechanisms [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Bacterial production of inactivating enzymes – The most common mechanism has been inactivation of the drug by phosphorylation (mediated by aminoglycoside kinases), adenylation, or acetylation (mediated by transferases) [<a href="#rid4">4,13-15</a>]. Inactivating enzymes can be encoded by plasmids or associated with transposable elements [<a href="#rid4">4,16</a>]. Plasmid exchange and dissemination of transposons facilitate the acquisition of drug resistance.</p><p></p><p class="bulletIndent1">Another mechanism of inactivation is methylation of 16S ribosomal RNA. This effect is mediated by an enzyme encoded by the rmtA gene and has been associated with high-level resistance to all parenteral aminoglycosides in current use [<a href="#rid16">16,17</a>]. Binding to the aminoacyl site on 16S ribosomal RNA is the mechanism by which aminoglycosides normally interfere with protein synthesis [<a href="#rid3">3,4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased permeability and reduced intracellular accumulation of the drug — Aminoglycoside resistance independent of inactivating enzymes has been known for some time in <em>P. aeruginosa</em> [<a href="#rid18">18</a>]. This resistance is characterized by resistance to all aminoglycosides and may be due to either to an efflux system or decreased drug permeability that results in reduced levels of aminoglycoside accumulation [<a href="#rid19">19</a>].</p><p></p><p>Multidrug-resistant organisms resistant to other antimicrobials (such as those producing extended-spectrum beta-lactamases [ESBLs] or carbapenemases) are often also resistant to most aminoglycosides due to aminoglycoside-modifying enzymes [<a href="#rid20">20</a>]. In contrast, certain aminoglycoside agents may retain activity despite resistance to other drugs in the class, depending on the mechanisms of resistance. <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">Plazomicin</a> often retains activity against <em>Klebsiella pneumoniae</em> carbapenemase (KPC)- or ESBL-producing Enterobacteriaceae despite the presence of aminoglycoside-modifying enzymes that inactivate other aminoglycosides [<a href="#rid21">21,22</a>]. However, in vitro evidence suggests poor activity against multidrug-resistant gram-negative <em>Pseudomonas</em> or <em>Acinetobacter</em> spp [<a href="#rid22">22</a>]. <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">Amikacin</a> has also been effective in some institutions against selected organisms with high rates of in vitro microbial resistance to <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> and <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a>. Rates of susceptibility to gentamicin and tobramycin have also been observed to improve after amikacin was introduced [<a href="#rid23">23,24</a>]. </p><p class="headingAnchor" id="H120096136"><span class="h2">Enterococci</span><span class="headingEndMark"> — </span>Enterococci are intrinsically resistant to aminoglycosides and can acquire resistance to high concentrations. However, the potential for synergy exists when enterococci are exposed to a combination of the aminoglycoside with a cell wall-active agent (such as penicillin or <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>) in the absence of high-level resistance (reported as “SYN-S”). (See <a class="local">'Combination antibacterial therapy'</a> below.)</p><p>The presence of high-level enterococcal resistance to aminoglycosides (MIC ≥500 mcg/mL of <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> or ≥2000 mcg/mL of <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a>, reported as “SYN-R”) eliminates the synergism expected between an aminoglycoside and a cell wall active agent. Different genetic mutations are responsible for high-level resistance to different aminoglycosides. (See  <a class="medical medical_review" href="/z/d/html/470.html" rel="external">"Mechanisms of antibiotic resistance in enterococci", section on 'Aminoglycoside resistance'</a>.)</p><p>A naturally occurring characteristic of <em>Enterococcus faecium</em> is moderate-level resistance to <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> (MICs 64 to 1000 mcg/mL) and resistance to synergism. This is due to the presence of an aminoglycoside modifying enzyme that modifies tobramycin but not <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> [<a href="#rid25">25</a>]. This enzyme also eliminates synergy between cell wall-active agents and tobramycin, kanamycin, and netilmicin. (See  <a class="medical medical_review" href="/z/d/html/470.html" rel="external">"Mechanisms of antibiotic resistance in enterococci"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">CLINICAL USE</span><span class="headingEndMark"> — </span>Despite the relatively broad spectrum of activity of aminoglycosides, their widespread clinical use is limited because of the availability of alternative, less toxic agents with comparable efficacy and without the need for serum drug concentration monitoring. In the United States, there are differences in the Food and Drug Administration-approved indications among the different aminoglycosides. </p><p>Aminoglycosides remain important as a second agent in treatment of serious infections due to aerobic gram-negative bacilli and certain gram-positive organisms and as part of a multidrug regimen for certain mycobacterial infections. There are rare instances (especially outside the urinary tract) in which monotherapy with aminoglycosides is adequate treatment.</p><p class="headingAnchor" id="H120095709"><span class="h2">Combination antibacterial therapy</span><span class="headingEndMark"> — </span>The most frequent clinical use of aminoglycosides (most commonly in combination with other antibacterial agents) is empiric therapy of serious infections, such as septicemia, nosocomial respiratory tract infections, complicated urinary tract infections, complicated intra-abdominal infections, and osteomyelitis caused by aerobic gram-negative bacilli. The intent of such therapy is to increase the chances that the pathogen is susceptible to at least one agent in the initial empiric combination. This strategy appears less relevant in settings where the incidence of antibiotic resistance is low (particularly given the risks of aminoglycoside-related adverse effects) or in patients at increased risk of aminoglycoside-induced toxicity [<a href="#rid26">26,27</a>]. </p><p>Once an organism has been identified and its susceptibilities determined to alternate agents, aminoglycosides are usually discontinued in favor of less toxic antibiotics to complete a treatment course. Combination therapy against gram-negative organisms is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3149.html" rel="external">"Gram-negative bacillary bacteremia in adults", section on 'Indications and rationale for combination therapy'</a> and  <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Role of combination antimicrobial therapy'</a>.)</p><p>Combination therapy with <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> is also used for the treatment of invasive enterococcal infections (such as endocarditis) not exhibiting high-level aminoglycoside resistance and (less often) for serious infections due to certain streptococci. However, even in some of these cases (as with enterococcal endocarditis) the toxicity of prolonged aminoglycosides has led to preferred use of other combination regimens. These uses are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">"Antimicrobial therapy of left-sided native valve endocarditis", section on 'Viridans streptococci and S. bovis/S. equinus complex'</a> and  <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">"Antimicrobial therapy of left-sided native valve endocarditis", section on 'Enterococci'</a> and  <a class="medical medical_review" href="/z/d/html/3163.html" rel="external">"Treatment of enterococcal infections", section on 'Clinical approach'</a> and  <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">"Antimicrobial therapy of left-sided native valve endocarditis", section on 'Streptococcal groups A, B, C, F, and G'</a>.)</p><p>Aminoglycosides are also used for definitive combination treatment of severe, invasive infections due to organisms such as <em>Brucella</em> spp and <em>Listeria monocytogenes</em>. (See  <a class="medical medical_review" href="/z/d/html/121314.html" rel="external">"Brucellosis: Treatment and prevention", section on 'Nonpregnant adults'</a> and  <a class="medical medical_review" href="/z/d/html/1303.html" rel="external">"Treatment and prevention of Listeria monocytogenes infection", section on 'Antibiotic therapy'</a>.)</p><p>Prophylactic use of aminoglycosides (in combination with either <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> or <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>) is usually restricted to select surgical procedures involving the gastrointestinal tract, urinary tract, or female genital tract in patients with allergies that preclude beta-lactam use [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/2147.html" rel="external">"Prevention of endocarditis: Antibiotic prophylaxis and other measures"</a> and  <a class="medical medical_review" href="/z/d/html/2545.html" rel="external">"Antibiotic prophylaxis for gastrointestinal endoscopic procedures"</a>.)</p><p class="headingAnchor" id="H120095722"><span class="h2">Antimycobacterial therapy</span><span class="headingEndMark"> — </span>Select aminoglycosides are useful for the treatment of drug resistant tuberculosis and certain nontuberculous mycobacterial infections (in combination with other antimycobacterial agents). These indications are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5347.html" rel="external">"Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/5341.html" rel="external">"Treatment of <i>Mycobacterium avium </i>complex pulmonary infection in adults", section on 'Regimen selection'</a> and  <a class="medical medical_review" href="/z/d/html/488.html" rel="external">"Antituberculous drugs: An overview", section on 'Injectable-only agents'</a>.)</p><p class="headingAnchor" id="H120095715"><span class="h2">Monotherapy</span><span class="headingEndMark"> — </span>There are few indications for monotherapy with systemic aminoglycosides:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tularemia</strong> – <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">Streptomycin</a> and <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> are first-line agents, although other options may be used in less severe cases. (See  <a class="medical medical_review" href="/z/d/html/3141.html" rel="external">"Tularemia: Clinical manifestations, diagnosis, treatment, and prevention", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Plague</strong> – <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">Streptomycin</a> and <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> are first-line agents, although other options may be used in patients who cannot tolerate aminoglycosides. (See  <a class="medical medical_review" href="/z/d/html/3131.html" rel="external">"Clinical manifestations, diagnosis, and treatment of plague (<i>Yersinia pestis</i> infection)", section on 'Alternative options'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urinary tract infections due to multidrug-resistant (MDR) gram-negative organisms</strong> – Aminoglycosides can be an option for select patients with MDR gram-negative infections when the organism is susceptible in vitro and other antibiotics are either impractical or contraindicated. Aminoglycosides achieve high concentration in the urinary tract, and in some cases (particularly with <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">plazomicin</a> as well as <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a>), retain activity against some gram-negative organisms resistant to many other classes of antibiotics. (See  <a class="medical medical_review" href="/z/d/html/471.html" rel="external">"Carbapenem-resistant <i>E. coli</i>, <i>K. pneumoniae</i>, and other Enterobacterales (CRE)", section on 'Isolates susceptible to standard-spectrum antibiotics'</a>.)</p><p></p><p class="bulletIndent1">Given their lack of predictable activity against MDR gram-negative organisms, susceptibility should be confirmed. Furthermore, the appropriateness of aminoglycoside use for invasive infections caused by carbapenem-resistant Enterobacteriaceae (CRE) is questionable (even in the setting of susceptibility in vitro), given the difficulty attaining pharmacodynamics targets in such settings with standard and high-dose regimens [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>N. gonorrhoeae</em></strong> – Spectinomycin is an alternate therapy for non-pharyngeal gonococcal infections in patients who have severe penicillin allergy. However, it is not available in the United States. The combination of <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> and <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> is also an alternative therapy for selected gonococcal infections for those who cannot use other regimens. (See  <a class="medical medical_review" href="/z/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents", section on 'Alternate regimens'</a>.) </p><p></p><p>Because of poor activity and/or penetration into lungs, abscesses, and the central nervous system, intravenous aminoglycosides should not be relied upon as monotherapy in infections that involve these sites.</p><p class="headingAnchor" id="H120095818"><span class="h2">Other aminoglycoside formulations</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">Paromomycin</a> is an oral, poorly absorbed aminoglycoside that is mainly used as treatment for intraintestinal amebic infection. (See  <a class="medical medical_review" href="/z/d/html/5727.html" rel="external">"Intestinal Entamoeba histolytica amebiasis", section on 'Symptomatic infection'</a>.)</p><p>Aminoglycosides are also available in topical, inhaled, intraventricular, intraperitoneal, and impregnated cement formulations for specific indications. (See  <a class="medical medical_review" href="/z/d/html/3810.html" rel="external">"Nosocomial infections in the intensive care unit: Epidemiology and prevention", section on 'Digestive and oropharyngeal decontamination'</a> and  <a class="medical medical_review" href="/z/d/html/7665.html" rel="external">"Prosthetic joint infection: Treatment", section on 'Resection arthroplasty with reimplantation'</a> and  <a class="medical medical_review" href="/z/d/html/16516.html" rel="external">"External otitis: Treatment", section on 'Antibiotics'</a> and  <a class="medical medical_review" href="/z/d/html/1882.html" rel="external">"Microbiology and therapy of peritonitis in peritoneal dialysis", section on 'Route of administration'</a> and  <a class="medical medical_review" href="/z/d/html/1301.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Treatment and prognosis", section on 'Intrathecal and intraventricular therapy'</a>.) </p><p class="headingAnchor" id="H4080767746"><span class="h1">DOSING AND MONITORING</span><span class="headingEndMark"> — </span>The initial dose and frequency of aminoglycosides are based upon method of administration, indication, dosing weight, and renal function. Dosing adjustments should be based upon the results of serum drug concentration monitoring. Certain populations have significant variability in dosing requirements, including (but not limited to) neonates and patients with burns, critical illness, renal impairment, and cystic fibrosis [<a href="#rid30">30,31</a>]. Dosing and monitoring of parenteral aminoglycosides are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/475.html" rel="external">"Dosing and administration of parenteral aminoglycosides"</a>.) </p><p class="headingAnchor" id="H8"><span class="h1">PHARMACODYNAMICS AND KINETICS</span><span class="headingEndMark"> — </span>Certain pharmacodynamic and kinetic properties of the aminoglycoside are important for their clinical application. The postantibiotic effect (PAE) and concentration-dependent killing characteristics of aminoglycosides allow dosing at an extended interval for certain infections, and the synergistic effect with cell wall-active agents has led to the use of aminoglycosides in combination with these agents for serious infections. Limitations in the distribution of aminoglycosides restrict their use for infections at certain anatomical sites.</p><p class="headingAnchor" id="H120094867"><span class="h2">Post-antibiotic effect</span><span class="headingEndMark"> — </span>The post-antibiotic effect (PAE) refers to the persistent suppression of bacterial growth that occurs after the drug has been removed in vitro or cleared by drug metabolism and excretion in vivo. Initially described for gram-negative bacilli, aminoglycosides also exhibit PAE against <em>S. aureus</em> but not against other gram-positive cocci. The duration of the PAE (approximately 3 hours [range 1 to 7.5 hours]) depends upon the method of evaluation and the organism studied [<a href="#rid32">32</a>]. In general, the PAE is longer for gram-negative organisms than gram-positive organisms. The duration of the PAE is reduced in the absence of polymorphonuclear leukocytes (PMNs) [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H120094873"><span class="h2">Concentration-dependent killing</span><span class="headingEndMark"> — </span>Concentration-dependent killing refers to the ability of higher concentrations of aminoglycosides (relative to the organism's MIC) to induce more rapid, and complete, killing of the pathogen [<a href="#rid34">34</a>]. Aminoglycosides exhibit concentration-dependent microbiologic activity in both in vivo and in vitro models. Achieving optimal peak concentrations of aminoglycosides with standard dosing regimens can be difficult, since efforts must be made to avoid sustained elevated trough concentrations (which can predispose to nephrotoxicity). Relative to traditional dosing methods, the consolidated dosing approach is more likely to achieve optimal peak concentrations that result in concentration-dependent killing [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/z/d/html/475.html" rel="external">"Dosing and administration of parenteral aminoglycosides"</a>.)</p><p class="headingAnchor" id="H120096521"><span class="h2">Synergistic effect</span><span class="headingEndMark"> — </span>A synergistic effect has been demonstrated in vitro for selected organisms when aminoglycosides are used in combination with other antibiotics, most often with cell wall-active agents (eg, beta-lactam antibiotics) [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H120094886"><span class="h2">Absorption and time to peak concentrations</span><span class="headingEndMark"> — </span>Peak serum aminoglycoside concentrations are observed approximately 30 to 60 minutes after termination of an intravenous infusion, or 30 to 90 minutes after an intramuscular injection. The aminoglycosides are not absorbed after oral administration. However, local instillation into the pleural space or peritoneal cavity can result in significant serum concentrations.</p><p class="headingAnchor" id="H120094892"><span class="h2">Distribution</span><span class="headingEndMark"> — </span>The volume of distribution of <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>, <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a>, and <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a> in adults ranges from 0.2 to 0.4 L/kg and is increased in patients with ascites, burns, pregnancy, critical illness, and other conditions (such as cystic fibrosis). For <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">plazomicin</a>, the volume of distribution was dependent on population, ranging from 13.3 to 18.5 L in healthy adult subjects to as much as 52.9 L in adult patients with bloodstream infections and hospital-acquired pneumonia [<a href="#rid37">37</a>]. </p><p>Aminoglycosides reach concentrations in the urine 25- to 100-fold that of serum. In contrast, they show poor penetration into the CSF, biliary tree, and bronchial secretions.</p><p class="headingAnchor" id="H120094911"><span class="h2">Elimination</span><span class="headingEndMark"> — </span>Approximately 99 percent of the administered dose is eliminated unchanged in the urine, primarily by glomerular filtration. The terminal half-life ranges from 1.5 to 3.5 hours in adults with normal renal function. The half-life is prolonged in neonates, infants, and patients with decreased renal function.</p><p>Aminoglycosides are effectively removed by both hemodialysis (continuous and intermittent) and peritoneal dialysis. As a result, supplemental doses after hemodialysis are generally required. (See  <a class="medical medical_review" href="/z/d/html/475.html" rel="external">"Dosing and administration of parenteral aminoglycosides", section on 'Intermittent hemodialysis'</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">TOXICITY</span><span class="headingEndMark"> — </span>The primary toxicities of aminoglycosides are nephrotoxicity and ototoxicity. Rarely, neuromuscular blockade can occur.</p><p class="headingAnchor" id="H28"><span class="h2">Nephrotoxicity</span><span class="headingEndMark"> — </span>The reported incidence of nephrotoxicity varies widely due to variations in study design, toxicity definitions, patient population, and concomitant risk factors. A reasonable estimate (depending on definition) may be 10 to 20 percent, even when careful patient selection and close monitoring is performed. While rates reported for <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">plazomicin</a> are less than those reported with other aminoglycosides (approximately 3 percent), data are limited to patients primarily with complicated urinary tract infections [<a href="#rid37">37</a>]. </p><p>In most cases, aminoglycoside nephrotoxicity is reversible. </p><p>Aminoglycoside-associated nephrotoxicity is discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7214.html" rel="external">"Manifestations of and risk factors for aminoglycoside nephrotoxicity"</a> and  <a class="medical medical_review" href="/z/d/html/7242.html" rel="external">"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity", section on 'Nephrotoxicity'</a>.)</p><p class="headingAnchor" id="H29"><span class="h2">Ototoxicity</span><span class="headingEndMark"> — </span>Aminoglycoside-induced ototoxicity may result in either vestibular or cochlear damage. Manifestations of vestibular toxicity include vertigo, disequilibrium, lightheadedness, nausea, vomiting, and ataxia, while the usual symptoms of cochlear toxicity are tinnitus and hearing loss. While ototoxicity can be transient in some cases, it can also be irreversible. In addition to serum drug concentration monitoring, coadministration of agents that may have a protective effect (such as <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">N-acetylcysteine</a>) is a possible preventive strategy in patients receiving long-term aminoglycoside therapy and/or with end-stage kidney disease [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/7242.html" rel="external">"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity", section on 'Prevention of ototoxicity'</a>.) </p><p>Aminoglycoside-associated ototoxicity is discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7242.html" rel="external">"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity", section on 'Ototoxicity'</a>.)</p><p class="headingAnchor" id="H30"><span class="h2">Neuromuscular blockade</span><span class="headingEndMark"> — </span>Neuromuscular blockade is a rare but serious adverse effect induced by aminoglycoside therapy. Most patients experiencing such reactions have disease states and/or concomitant drug therapy that interfere with neuromuscular transmission. </p><p>For patients with myasthenia gravis, we recommend avoiding aminoglycosides altogether, regardless of dosing method.</p><p class="headingAnchor" id="H31"><span class="h1">DRUG INTERACTIONS</span><span class="headingEndMark"> — </span>The aminoglycosides can interact with a variety of other drugs causing increased toxicity and/or decreased efficacy. Specific interactions may be reviewed using the <a class="external" href="/drug-interactions">drug interactions program</a>. This tool can be accessed from the UpToDate search page as well as on individual drug information topics in the section entitled "Drug interactions."</p><p class="headingAnchor" id="H21514871"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Aminoglycosides bind to the aminoacyl site of 16S ribosomal RNA and disrupt bacterial peptide elongation, which is usually bactericidal against susceptible aerobic gram-negative bacilli. Microbiologic activity is pH-dependent, and acidic environments, like those found in the lung and bronchial secretions, may decrease the antimicrobial effect. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aminoglycosides exhibit potent in vitro activity against a wide range of aerobic gram-negative pathogens; <em>Burkholderia cepacia</em> and <em>Stenotrophomonas maltophilia</em> are particular exceptions. <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">Gentamicin</a> usually demonstrates superior in vitro activity to <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> against <em>Serratia</em> spp, while tobramycin is usually more potent than gentamicin against <em>Pseudomonas aeruginosa</em>. <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">Plazomicin</a> retains activity against many Enterobacteriaceae isolates resistant to other agents. Aminoglycosides (most notably <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a> and <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a>) are also active against mycobacteria. (See <a class="local">'Spectrum of activity'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Emergence of aminoglycoside resistance during treatment of gram-negative infections is infrequent but can occur through bacterial production of enzymes that inactivate the drug or methylate the target 16S ribosomal RNA and through an efflux system that decreases aminoglycoside accumulation. Enterococci are intrinsically resistant to moderate levels of aminoglycosides. The potential for synergy in combination with a cell wall-active agent remains unless the enterococcus has acquired high-level resistance to aminoglycosides. (See <a class="local">'Resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aminoglycosides are most frequently used in combination with another antibacterial agent for initial empiric therapy of septicemia, nosocomial respiratory tract infections, complicated urinary tract infections, complicated intra-abdominal infections, and osteomyelitis caused by aerobic gram-negative bacilli. They are often discontinued in favor of less toxic antibiotics once organism identity and susceptibility has been confirmed. (See <a class="local">'Clinical use'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Combination therapy with <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> is also used for the treatment of invasive infections caused by enterococci in the absence of high-level resistance. (See <a class="local">'Clinical use'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parenteral aminoglycosides are also used as part of a regimen for mycobacterial infections, and as a single agent for the treatment of tularemia, plague, and uncomplicated urinary tract infections caused by drug-resistant gram-negative organisms. (See <a class="local">'Clinical use'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The initial dose and frequency of aminoglycosides depend on method of administration, indication, dosing weight, and renal function. Dosing adjustments should be based upon the results of serum drug concentration monitoring. Certain populations have significant variability in dosing requirements. Dosing and monitoring of parenteral aminoglycosides is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/475.html" rel="external">"Dosing and administration of parenteral aminoglycosides"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aminoglycosides demonstrate both post-antibiotic effect and concentration-dependent killing. Aminoglycosides reach concentrations in the urine 25- to 100-fold that of serum but have poor penetration into the CSF, biliary tree, and bronchial secretions. They are effectively removed by both hemodialysis and peritoneal dialysis. (See <a class="local">'Mechanism of action'</a> above and <a class="local">'Pharmacodynamics and kinetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The primary toxicities of aminoglycosides are nephrotoxicity, which is generally reversible, and ototoxicity, both vestibular and cochlear. Neuromuscular blockade is a rare but serious adverse effect. (See <a class="local">'Toxicity'</a> above and  <a class="medical medical_review" href="/z/d/html/7214.html" rel="external">"Manifestations of and risk factors for aminoglycoside nephrotoxicity"</a> and  <a class="medical medical_review" href="/z/d/html/7242.html" rel="external">"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kumana CR, Yuen KY. Parenteral aminoglycoside therapy. Selection, administration and monitoring. Drugs 1994; 47:902.</a></li><li class="breakAll">Gilbert DN. Aminoglycosides. In: Principles and Practice of Infectious Diseases, 6th Ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, New York 2005. p.328.</li><li><a class="nounderline abstract_t">Fourmy D, Recht MI, Blanchard SC, Puglisi JD. Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science 1996; 274:1367.</a></li><li><a class="nounderline abstract_t">Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 1999; 43:727.</a></li><li><a class="nounderline abstract_t">Nanavaty J, Mortensen JE, Shryock TR. The effects of environmental conditions on the in vitro activity of selected antimicrobial agents against Escherichia coli. Curr Microbiol 1998; 36:212.</a></li><li><a class="nounderline abstract_t">Heffernan AJ, Sime FB, Lim SMS, et al. Impact of the Epithelial Lining Fluid Milieu on Amikacin Pharmacodynamics Against Pseudomonas aeruginosa. Drugs R D 2021; 21:203.</a></li><li><a class="nounderline abstract_t">Heffernan AJ, Sime FB, Sarovich DS, et al. Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic In Vitro Hollow-Fiber Infection Model. Antimicrob Agents Chemother 2020; 64.</a></li><li><a class="nounderline abstract_t">Moellering RC Jr. In vitro antibacterial activity of the aminoglycoside antibiotics. Rev Infect Dis 1983; 5:S212.</a></li><li><a class="nounderline abstract_t">Castanheira M, Sader HS, Mendes RE, Jones RN. Activity of Plazomicin Tested against Enterobacterales Isolates Collected from U.S. Hospitals in 2016-2017: Effect of Different Breakpoint Criteria on Susceptibility Rates among Aminoglycosides. Antimicrob Agents Chemother 2020; 64.</a></li><li><a class="nounderline abstract_t">Fleischmann WA, Greenwood-Quaintance KE, Patel R. In Vitro Activity of Plazomicin Compared to Amikacin, Gentamicin, and Tobramycin against Multidrug-Resistant Aerobic Gram-Negative Bacilli. Antimicrob Agents Chemother 2020; 64.</a></li><li><a class="nounderline abstract_t">Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.</a></li><li><a class="nounderline abstract_t">Daley CL, Iaccarino JM, Lange C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis 2020; 71:e1.</a></li><li><a class="nounderline abstract_t">Davies J, Wright GD. Bacterial resistance to aminoglycoside antibiotics. Trends Microbiol 1997; 5:234.</a></li><li><a class="nounderline abstract_t">Hon WC, McKay GA, Thompson PR, et al. Structure of an enzyme required for aminoglycoside antibiotic resistance reveals homology to eukaryotic protein kinases. Cell 1997; 89:887.</a></li><li><a class="nounderline abstract_t">Daigle DM, McKay GA, Wright GD. Inhibition of aminoglycoside antibiotic resistance enzymes by protein kinase inhibitors. J Biol Chem 1997; 272:24755.</a></li><li><a class="nounderline abstract_t">Doi Y, Arakawa Y. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin Infect Dis 2007; 45:88.</a></li><li><a class="nounderline abstract_t">Yokoyama K, Doi Y, Yamane K, et al. Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa. Lancet 2003; 362:1888.</a></li><li><a class="nounderline abstract_t">Poole K. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49:479.</a></li><li><a class="nounderline abstract_t">Westbrock-Wadman S, Sherman DR, Hickey MJ, et al. Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability. Antimicrob Agents Chemother 1999; 43:2975.</a></li><li><a class="nounderline abstract_t">Haidar G, Alkroud A, Cheng S, et al. Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum-β-Lactamase-Producing Enterobacter Species. Antimicrob Agents Chemother 2016; 60:5208.</a></li><li><a class="nounderline abstract_t">Thwaites M, Hall D, Shinabarger D, et al. Evaluation of the Bactericidal Activity of Plazomicin and Comparators against Multidrug-Resistant Enterobacteriaceae. Antimicrob Agents Chemother 2018; 62.</a></li><li><a class="nounderline abstract_t">Castanheira M, Davis AP, Mendes RE, et al. In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes. Antimicrob Agents Chemother 2018; 62.</a></li><li><a class="nounderline abstract_t">Gerding DN, Larson TA, Hughes RA, et al. Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother 1991; 35:1284.</a></li><li><a class="nounderline abstract_t">King JW, White MC, Todd JR, Conrad SA. Alterations in the microbial flora and in the incidence of bacteremia at a university hospital after adoption of amikacin as the sole formulary aminoglycoside. Clin Infect Dis 1992; 14:908.</a></li><li><a class="nounderline abstract_t">Costa Y, Galimand M, Leclercq R, et al. Characterization of the chromosomal aac(6')-Ii gene specific for Enterococcus faecium. Antimicrob Agents Chemother 1993; 37:1896.</a></li><li><a class="nounderline abstract_t">Ong DSY, Frencken JF, Klein Klouwenberg PMC, et al. Short-Course Adjunctive Gentamicin as Empirical Therapy in Patients With Severe Sepsis and Septic Shock: A Prospective Observational Cohort Study. Clin Infect Dis 2017; 64:1731.</a></li><li><a class="nounderline abstract_t">Ong DSY, van Werkhoven CH, Cremer OL, et al. Is a randomized trial of a short course of aminoglycoside added to β-lactam antibiotics for empirical treatment in critically ill patients with sepsis justified? Clin Microbiol Infect 2018; 24:95.</a></li><li><a class="nounderline abstract_t">Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013; 70:195.</a></li><li><a class="nounderline abstract_t">Zavascki AP, Klee BO, Bulitta JB. Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility. Expert Rev Anti Infect Ther 2017; 15:519.</a></li><li><a class="nounderline abstract_t">Marsot A, Guilhaumou R, Riff C, Blin O. Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies. Clin Pharmacokinet 2017; 56:127.</a></li><li><a class="nounderline abstract_t">Jenkins A, Thomson AH, Brown NM, et al. Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review. J Antimicrob Chemother 2016; 71:2754.</a></li><li><a class="nounderline abstract_t">Novelli A, Mazzei T, Fallani S, et al. In vitro postantibiotic effect and postantibiotic leukocyte enhancement of tobramycin. J Chemother 1995; 7:355.</a></li><li><a class="nounderline abstract_t">Fantin B, Ebert S, Leggett J, et al. Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli. J Antimicrob Chemother 1991; 27:829.</a></li><li><a class="nounderline abstract_t">McLean AJ, IoannidesDemos LL, Li SC, et al. Bactericidal effect of gentamicin peak concentration provides a rationale for administration of bolus doses. J Antimicrob Chemother 1993; 32:301.</a></li><li><a class="nounderline abstract_t">Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997; 39:677.</a></li><li><a class="nounderline abstract_t">Allan JD, Moellering RC Jr. Management of infections caused by gram-negative bacilli: the role of antimicrobial combinations. Rev Infect Dis 1985; 7 Suppl 4:S559.</a></li><li class="breakAll">Achaogen. Antimicrobial Drugs Advisory Committee Meeting Briefing Book: Plazomicin. May 2, 2018. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM606040.pdf (Accessed on July 18, 2018).</li><li><a class="nounderline abstract_t">Vural A, Koçyiğit İ, Şan F, et al. Long-Term Protective Effect of N-Acetylcysteine against Amikacin-Induced Ototoxicity in End-Stage Renal Disease: A Randomized Trial. Perit Dial Int 2018; 38:57.</a></li></ol></div><div id="topicVersionRevision">Topic 483 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7521830" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Parenteral aminoglycoside therapy. Selection, administration and monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7521830" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Parenteral aminoglycoside therapy. Selection, administration and monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8910275" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10103173" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Aminoglycosides: activity and resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9504987" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The effects of environmental conditions on the in vitro activity of selected antimicrobial agents against Escherichia coli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33797739" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Impact of the Epithelial Lining Fluid Milieu on Amikacin Pharmacodynamics Against Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32660986" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic In Vitro Hollow-Fiber Infection Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : In vitro antibacterial activity of the aminoglycoside antibiotics</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32094137" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Activity of Plazomicin Tested against Enterobacterales Isolates Collected from U.S. Hospitals in 2016-2017: Effect of Different Breakpoint Criteria on Susceptibility Rates among Aminoglycosides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31712206" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : In Vitro Activity of Plazomicin Compared to Amikacin, Gentamicin, and Tobramycin against Multidrug-Resistant Aerobic Gram-Negative Bacilli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27516382" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32628747" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9211644" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Bacterial resistance to aminoglycoside antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9200607" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Structure of an enzyme required for aminoglycoside antibiotic resistance reveals homology to eukaryotic protein kinases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9312069" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Inhibition of aminoglycoside antibiotic resistance enzymes by protein kinase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17554708" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14667745" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15673721" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Aminoglycoside resistance in Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10582892" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27297487" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum-β-Lactamase-Producing Enterobacter Species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29866876" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Evaluation of the Bactericidal Activity of Plazomicin and Comparators against Multidrug-Resistant Enterobacteriaceae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29866862" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1929283" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1576287" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Alterations in the microbial flora and in the incidence of bacteremia at a university hospital after adoption of amikacin as the sole formulary aminoglycoside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8239603" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Characterization of the chromosomal aac(6')-Ii gene specific for Enterococcus faecium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329088" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Short-Course Adjunctive Gentamicin as Empirical Therapy in Patients With Severe Sepsis and Septic Shock: A Prospective Observational Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28989114" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Is a randomized trial of a short course of aminoglycoside added toβ-lactam antibiotics for empirical treatment in critically ill patients with sepsis justified?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23327981" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical practice guidelines for antimicrobial prophylaxis in surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28375030" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27324191" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27494904" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8568546" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : In vitro postantibiotic effect and postantibiotic leukocyte enhancement of tobramycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1938689" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8226432" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Bactericidal effect of gentamicin peak concentration provides a rationale for administration of bolus doses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9222035" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Once-daily dosing of aminoglycosides: review and recommendations for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3909313" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Management of infections caused by gram-negative bacilli: the role of antimicrobial combinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3909313" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Management of infections caused by gram-negative bacilli: the role of antimicrobial combinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097487" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Long-Term Protective Effect of N-Acetylcysteine against Amikacin-Induced Ototoxicity in End-Stage Renal Disease: A Randomized Trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
